Chemotherapy of Advanced Neuroblastoma: Does Adriamycin Contribute?

Overview

Journal Arch Dis Child

Specialty Pediatrics

Date 1981 Jul 1

PMID 7271289

Citations 8

Authors

J NINANE

J Pritchard

J S MALPAS

Affiliations

Soon will be listed here.

Abstract

Between 1970 and 1977, 69 children with newly diagnosed stage III or IV neuroblastoma were treated with pulses of either cyclophosphamide and vincristine (CV) (n = 23), or cyclophosphamide, vincristine, and adriamycin (CVA) (n = 46). The 'complete' and partial response rates were 35 and 22% to CV, and 43 and 26% to CVA. For 'complete' responders the median time to relapse was 18 months for those treated with CV, and 17 months for those treated CVA; for partial responders the times were 5 and 7 months respectively. At 2 1/2 years only 17% of the CV patients and only 13% of the CVA patients were alive and free of disease, giving a 15% overall survival rate. The addition of adriamycin to cyclophosphamide and vincristine did not significantly improve the response rate, duration of response, or survival in these children with advanced neuroblastoma. The previously noted favourable effects of age less than 1 year at diagnosis and of female sex were confirmed. The equally poor survival for stage III and stage IV patients justifies the inclusion of stage III patients in a bad prognosis group.

Citing Articles

The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis.

Frappaz D, Perol D, Michon J, Berger C, Coze C, Bernard J Br J Cancer. 2002; 87(11):1197-203.

PMID: 12439705 PMC: 2408899. DOI: 10.1038/sj.bjc.6600627.

Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin.

Lowis S, Pearson A, Reid M, Craft A Cancer Chemother Pharmacol. 1993; 31(5):415-8.

PMID: 8431977 DOI: 10.1007/BF00686158.

Stage II neuroblastoma. Adverse prognostic significance of lymph node involvement.

NINANE J, Pritchard J, Morris Jones P, Mann J, MALPAS J Arch Dis Child. 1982; 57(6):438-42.

PMID: 7092308 PMC: 1627662. DOI: 10.1136/adc.57.6.438.

High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.

Pritchard J, McElwain T Br J Cancer. 1982; 45(1):86-94.

PMID: 7037033 PMC: 2010954. DOI: 10.1038/bjc.1982.11.

High dose melphalan in children with advanced malignant disease. A pharmacokinetic study.

NINANE J, Baurain R, de Selys A, Trouet A, Cornu G Cancer Chemother Pharmacol. 1985; 15(3):263-7.

PMID: 4053270 DOI: 10.1007/BF00263898.

References

Leikin S, Evans A, Heyn R, Newton W . The impact of chemotherapy on advanced neuroblastoma. Survival of patients diagnosed in 1956, 1962, and 1966-68 in Children's Cancer Study Group A. J Pediatr. 1974; 84(1):131-4. DOI: 10.1016/s0022-3476(74)80574-3. View

McElwain T, Hedley D, Gordon M, Jarman M, Millar J, Pritchard J . High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol. 1979; 7 Suppl 5:360-71. View

SELAWRY O, HOLLAND J, WOLMAN I . Effect of vincristine (NSC-67574) on malignant solid tumors in children. Cancer Chemother Rep. 1968; 52(4):497-500. View

Evans A, DAngio G, Randolph J . A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer. 1971; 27(2):374-8. DOI: 10.1002/1097-0142(197102)27:2<374::aid-cncr2820270221>3.0.co;2-g. View

Breslow N, McCann B . Statistical estimation of prognosis for children with neuroblastoma. Cancer Res. 1971; 31(12):2098-103. View

Gasparini M, Bellani F, Musumeci R, Bonadonna G . Response and survival of patients with metastatic neuroblastoma after combination chemotherapy with adriamycin (NSC-123127), cyclophosphamide (NSC-26271), and vincristine (NSC-67574). Cancer Chemother Rep. 1974; 58(3):365-70. View

Wilson L, Draper G . Neuroblastoma, its natural history and prognosis: a study of 487 cases. Br Med J. 1974; 3(5926):301-7. PMC: 1611711. DOI: 10.1136/bmj.3.5926.301. View

HEYN R, Holland R, NEWTON Jr W, Tefft M, Breslow N, HARTMANN J . The role of combined chemotherapy in the treatment of rhabdomyosarcoma in children. Cancer. 1974; 34(6):2128-42. DOI: 10.1002/1097-0142(197412)34:6<2128::aid-cncr2820340638>3.0.co;2-m. View

Devita Jr V, Young R, Canellos G . Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer. 1975; 35(1):98-110. DOI: 10.1002/1097-0142(197501)35:1<98::aid-cncr2820350115>3.0.co;2-b. View

10.

Jaffe N . Neuroblastoma: review of the literature and an examination of factors contributing to its enigmatic charcter. Cancer Treat Rev. 1976; 3(2):61-82. DOI: 10.1016/s0305-7372(76)80005-9. View

11.

Hayes F, Green A, Mauer A . Correlation of cell kinetic and clinical response to chemotherapy in disseminated neuroblastoma. Cancer Res. 1977; 37(10):3766-70. View

12.

Rivera G, Green A, Hayes A, Avery T, Pratt C . Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma. Cancer Treat Rep. 1977; 61(7):1243-8. View

13.

Nitschke R, Starling K, Vats T, Bryan H . Cis-diamminedichloroplatinum (NSC-119875) in childhood malignancies: a Southwest Oncology Group study. Med Pediatr Oncol. 1978; 4(2):127-32. DOI: 10.1002/mpo.2950040208. View

14.

Finklestein J, KLEMPERER M, Evans A, Bernstein I, Leikin S, McCreadie S . Multiagent chemotherapy for children with metastatic neuroblastoma: a report from Childrens Cancer Study Group. Med Pediatr Oncol. 1979; 6(2):179-88. DOI: 10.1002/mpo.2950060211. View

15.

Evans A, HEYN R, NEWTON Jr W, LEIKIN S . Vincristine sulfate and cyclophosphamide for children with metastatic neuroblastoma. JAMA. 1969; 207(7):1325-7. View